Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 13

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 1
Chunk 13
---
 segments and to evaluate the performance of certain employees for the determination of compensation.  The CODM reviews forecast-to-actual variances in segment sales and operating profit on a monthly basis when making decisions about allocating capital and personnel to the segments. The table below reconciles segment sales to segment operating profit with the expense categories presented reflecting the expenses that the Company has determined to be significant segment expenses.  Significant segment expenses are the expense category details regularly provided to the CODM to allocate resources to the segments and to evaluate segment performance.  Detailed segment data for the three and nine-month periods ended September 26, 2025 and September 27, 2024 is as follows ($ in millions):BiotechnologyLife SciencesDiagnosticsOther(a)TotalFor the Three-Month Period Ended September 26, 2025:Sales$1,798 $1,792 $2,463 $— $6,053 Less:Depreciation(38)(47)(101)(3)(189)Amortization of intangible assets(231)(154)(48)— (433)Impairments(b)(86)— (15)— (101)Other segment expenses(c)(1,091)(1,369)(1,634)(82)(4,176)Operating profit$352 $222 $665 $(85)$1,154 For the Three-Month Period Ended September 27, 2024:Sales$1,653 $1,782 $2,363 $— $5,798 Less:Depreciation(36)(44)(95)(2)(177)Amortization of intangible assets(218)(147)(49)— (414)Impairments(b)— (222)— — (222)Other segment expenses(c)(1,009)(1,334)(1,604)(80)(4,027)Operating profit (loss)$390 $35 $615 $(82)$958 

11

BiotechnologyLife SciencesDiagnosticsOther(a)TotalFor the Nine-Month Period Ended September 26, 2025:Sales$5,260 $5,249 $7,221 $— $17,730 Less:Depreciation(110)(137)(301)(7)(555)Amortization of intangible assets(672)(453)(144)— (1,269)Impairments(b)(101)(432)(15)— (548)Other segment